Systemic scleroderma (SSC or systemic sclerosis) is an autoimmune disorder that results into scar tissues (fibrosis) on the skin and internal organs. The prevalence of systemic scleroderma is about 30-500 cases in 1 million with more common in women than men.Know more about the disease, its causes, symptoms and diagnosis through the newsletter. DelveInsight brings to focus an autoimmune skin disorder that can be due to either or a combination of genetic and environmental factors.The newsletter compiles the <a href="https://www.delveinsight.com/report-store/systemic-scleroderma-epidemiology-forecast" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 71, 178);">Systemic scleroderma epidemiology insights</a>, treatment modalities, unmet needs prevalent and the emerging therapies in the <a href="https://www.delveinsight.com/report-store/systemic-scleroderma-market" rel="noopener noreferrer" target="_blank" style="color: rgb(0, 71, 178);">Systemic Scleroderma Market</a>. It also focuses on recent ongoings on the R&amp;D front, news coverings, major pharma players involved and collaborations and funding taking place in the domain.Get the newsletter directly mailed to your email box by filling up a simple form towards your right. Join our Newsletter series and get rich insights delivered every week to you.

Systemic scleroderma (SSC or systemic sclerosis) is an autoimmune disorder that results into scar tissues (fibrosis) on the skin and internal organs. The prevalence of systemic scleroderma is about 30-500 cases in 1 million with more common in women than men. Know more about the disease, its causes, symptoms and diagnosis through the newsletter. DelveInsight brings to focus an autoimmune skin disorder that can be due to either or a combination of genetic and environmental factors. 

Systemic Scleroderma

The Systemic Scleroderma newsletter compiles the epidemiological scenario, treatment modalities, unmet needs prevalent and the emerging therapies in the SSD Market